EUCTR2010-023869-21-FI
Active, not recruiting
Not Applicable
A study of erlotinib (Tarceva®) treatment in patients with locally advanced or metastatic non-small cell lunf cancer who present activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor
Conditionsocally advanced or metastatic non-small cell lung cancer with activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor.MedDRA version: 14.0Level: LLTClassification code 10025054Term: Lung cancer non-small cell stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
DrugsTarceva®
Overview
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- Roche Oy
Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1\. Patients able and willing to give written informed consent. Consent must be obtained prior to any study\-specific procedure.
- •2\. Histologically or cytologically documented inoperable, locally advanced (inoperable and not eligible for chemoradiotherapy stage IIIB) or metastatic (stage IV) NSCLC disease who present activating mutations (exon 19 deletions or exon 21 substitution L858R) in the tyrosine kinase domain of EGFR.
- •3\. Measurable disease must be characterized according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria or according to standard of care.
- •4\. Male or female patients aged \= 18 years.
- •5\. Eastern Cooperative Oncology Group (ECOG) performance status 0\-2\.
- •6\. Life expectancy \= 12 weeks.
- •7\. Adequate hematological function: Absolute neutrophil count (ANC) \= 1\.5 x 109/L, and Platelet count \= 100 x 109/L, and Hemoglobin \= 9 g/dL (may be transfused to maintain or exceed this level).
- •8\. Adequate liver function: Total bilirubin \< 1\.5 x upper limit of normal (ULN), and aspartate aminotransferase (ASAT) and/or alanine aminotransferase (ALAT) \< 2\.5 x ULN in patients without liver metastases; \< 5 x ULN in patients with liver metastases.
- •9\. Adequate renal function: Serum creatinine \= 1\.25 x ULN.
- •10\. Able to comply with the required protocol and follow\-up procedures, and able to receive oral medications.
Exclusion Criteria
- •1\. Previous treatment with chemotherapy or therapy against EGFR, either with antibody or small molecule (tyrosine kinase inhibitor) for metastatic disease. The administration of neoadjuvant or adjuvant therapy is allowed as long as it has finalized ³ 6 months before entering the study. Patients can have received radiotherapy as long as the irradiated lesion is not the only target lesion for evaluating response and as long as radiotherapy has been completed before initiating the study treatment (a 2\-week period is recommended).
- •2\. Treatment with an investigational drug agent during the 3 weeks before enrollment in the study.
- •3\. History of another neoplasm other than carcinoma in situ of the uterine cervix, basal cell skin carcinoma treated adequately, or prostate carcinoma with a good prognosis (Gleason £ 6\) treated radically. History of another neoplasm treated curatively and without evidence of disease in the last 5 years.
- •4\. Patients with symptomatic cerebral metastases.
- •5\. Known hypersensitivity to erlotinib or any of its excipients.
- •6\. Any significant ophthalmologic abnormality, especially severe dry eye syndrome,
- •keratoconjunctivitis sicca, Sjögrens syndrome, severe exposure keratitis or any other disorder likely to increase the risk of corneal epithelial lesions. The use of contact lenses is not recommended during the study. The decision to continue to wear contact lenses should be discussed with the patient’s treating oncologist and the ophthalmologist.
- •7\. Coumarins (CoumadinTM; warfarin) use. If the patient requires anti\-coagulation therapy, the use of low molecular weight heparin instead of coumarins is recommended where clinically possible.
- •8\. Unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease).
- •9\. Evidence of any other disease, neurological or metabolic dysfunction, physical examination or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment\-related complications.
Investigators
Similar Trials
Active, not recruiting
Not Applicable
A Phase IIIb Study of Tarceva (Erlotinib) in patients with locally advanced, unresectable or metastatic pancreatic cancer - TARCEVA - EAP in pancreatic carcinomaocally advanced, unresectable or metastatic pancreatic cancer (adenocarcinoma)MedDRA version: 14.1Level: PTClassification code 10033610Term: Pancreatic carcinoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2005-004605-29-ITROCHE
Active, not recruiting
Not Applicable
Pharmacodynamic study of Erlotinib (Tarceva) in patients with mestastatic or locally advanced Epidermoid carcinoma of the head and neckMestastatic or locally advanced Epidermoid carcinoma of the head and neckEUCTR2005-003814-14-ESnidad Integral de Investigación en Oncología, S.L.49
Active, not recruiting
Not Applicable
A parallel phase II study of Tarceva® (Erlotinib) in patients with advanced non-small cell lung cancer (Stage IIIB/IV) not pre-treated by chemotherapy including dose escalation to toxicity in current and former smokersPatients with advanced NSCLC not previously treated with chemotherapyEUCTR2005-004782-41-DEF. Hoffmann-La Roche Ltd44
Active, not recruiting
Phase 1
A parallel phase II study of Tarceva® (Erlotinib) in patients with advanced non-small cell lung cancer (Stage IIIB/IV) not pre-treated by chemotherapy including dose escalation to toxicity in current and former smokersPatients with advanced NSCLC not previously treated with chemotherapyEUCTR2005-004782-41-GBF. Hoffmann-La Roche Ltd44
Active, not recruiting
Not Applicable
A parallel phase II study of Tarceva® (Erlotinib) in patients with advanced non-small cell lung cancer (Stage IIIB/IV) not pre-treated by chemotherapy including dose escalation to toxicity in current and former smokersPatients with advanced NSCLC not previously treated with chemotherapyMedDRA version: 8.1Level: LLTClassification code 10029521Term: Non-small cell lung cancer stage IIIBEUCTR2005-004782-41-NLF. Hoffmann-La Roche Ltd44